Literature DB >> 1872339

CA 125 regression: a model for epithelial ovarian cancer response.

R E Buller1, M L Berman, J D Bloss, A Manetta, P J DiSaia.   

Abstract

The rate of decline of CA 125 in effectively treated epithelial ovarian cancer is described by the exponential regression curve CA 125 = EXP [i - s (days after surgery)]. In this equation i, the y-axis intercept, measures initial tumor burden whereas s, the slope of the regression curve, is determined by the extent of cytoreductive surgery and the subsequent response to chemotherapy. Departure from the regression curve uniformly results in progressive disease. In patients whose cancers had been completely removed, we calculated the mean half-life of CA 125 to be 10.4 days (range 4 to 21). In this case s = 0.0835 and characterizes the ideal regression rate. The model predicts that high-dose cisplatin chemotherapy (s = 0.0671) is more effective than low-dose cisplatin (s = 0.0380) (p less than 0.03) in eliminating residual cancer. Because s can be calculated within 2 to 3 months of treatment and then compared with s for the ideal regression curve and with the values of s reported for standard chemotherapy, evaluation of any new treatment protocol can be facilitated with this method.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1872339     DOI: 10.1016/0002-9378(91)90093-7

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  8 in total

1.  Assessment of CA-125 area under the curve as a prognostic factor in patients with ovarian cancer.

Authors:  Sernaz Uzunoglu; Aysun Aybatlı; Petek Balkanlı Kaplan; Irfan Cicin; Necdet Sut; Cenk Sayın; Fusun Varol
Journal:  Med Oncol       Date:  2013-01-16       Impact factor: 3.064

2.  Identification of Siglec-9 as the receptor for MUC16 on human NK cells, B cells, and monocytes.

Authors:  Jennifer A Belisle; Sachi Horibata; Gubbels A A Jennifer; Sarah Petrie; Arvinder Kapur; Sabine André; Hans-Joachim Gabius; Claudine Rancourt; Joseph Connor; James C Paulson; Manish S Patankar
Journal:  Mol Cancer       Date:  2010-05-24       Impact factor: 27.401

3.  Significance of postoperative CA-125 decline after cytoreductive surgery in stage IIIC/IV ovarian cancer.

Authors:  Seung-Chul Yoo; Jong-Hyuck Yoon; Mi-Ok Lyu; Woo Young Kim; Suk-Joon Chang; Ki-Hong Chang; Hee-Sug Ryu
Journal:  J Gynecol Oncol       Date:  2008-09-30       Impact factor: 4.401

Review 4.  CA125-related tumor cell kinetics variables after chemotherapy in advanced ovarian cancer: a systematic review.

Authors:  G Colloca; A Venturino; I Governato
Journal:  Clin Transl Oncol       Date:  2015-11-06       Impact factor: 3.405

5.  CA 125 half-life in ovarian cancer: a multivariate survival analysis.

Authors:  C A Yedema; P Kenemans; F Voorhorst; G Bon; C Schijf; L Beex; A Verstraeten; J Hilgers; J Vermorken
Journal:  Br J Cancer       Date:  1993-06       Impact factor: 7.640

6.  Prognostic Significance of CA125 Dynamic Change for Progression Free Survival in Patients with Epithelial Ovarian Carcinoma.

Authors:  Zemin Li; Han Yin; Mulan Ren; Yang Shen
Journal:  Med Sci Monit       Date:  2020-09-10

7.  Characterisation and clinical usefulness of CA130 antigen recognised by monoclonal antibodies, 130-22 and 145-9, in ovarian cancers.

Authors:  H Kobayashi; H Ohi; T Fujii; T Terao
Journal:  Br J Cancer       Date:  1993-02       Impact factor: 7.640

8.  Clinical Significance of CA125 Level after the First Cycle of Chemotherapy on Survival of Patients with Advanced Ovarian Cancer.

Authors:  Maria Lee; Min Young Chang; Hanna Yoo; Kyung Eun Lee; Doo Byung Chay; Hanbyoul Cho; Sunghoon Kim; Young Tae Kim; Jae-Hoon Kim
Journal:  Yonsei Med J       Date:  2016-05       Impact factor: 2.759

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.